Business Day TV spoke to Adcock Ingram CEO Andy Hall about the company’s annual results
26 August 2021 - 08:34
byBusiness Day TV
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
A sign outside the Adcock Ingram offices in Johannesburg. Picture: REUTERS
Adcock Ingram has posted a 6% rise in annual revenue, helped by strong demand for immune-boosting products, as well as some linked to the treatment of Covid-19.
The pharmaceutical manufacturer’s earnings, however, took a knock.
Alishia Seckam spoke to CEO Andy Hall for more detail.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
News leader
WATCH: Why Adcock Ingram’s earnings fell
Business Day TV spoke to Adcock Ingram CEO Andy Hall about the company’s annual results
Adcock Ingram has posted a 6% rise in annual revenue, helped by strong demand for immune-boosting products, as well as some linked to the treatment of Covid-19.
The pharmaceutical manufacturer’s earnings, however, took a knock.
Alishia Seckam spoke to CEO Andy Hall for more detail.
Adcock Ingram eyes broad-based growth after striking product balance
Adcock Ingram to shift product mix to protect its profit margins
Adcock pledges to help speed up access to Covid-19 therapeutics
Companies in this Story
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.